Anika Fully Enrolls Second Phase III CINGAL Trial

Anika Therapeutics completed enrollment of 576 patients in its second pivotal Phase III trial evaluating CINGAL® hyaluronic acid/corticosteroid viscosupplement for the treatment of knee osteoarthritis symptoms.

CINGAL combines triamcinolone hexacetonide, an FDA-cleared steroid utilized to treat inflammation, with cross-linked,...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0